Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AC Immune SA - Common Stock (NQ:ACIU)

2.770 +0.050 (+1.84%)
Streaming Delayed Price Updated: 12:35 PM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AC Immune SA - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
From AC Immune SA
Via GlobeNewswire
News headline image
RH Posts Mixed Q1 Results, Joins MSC Industrial Direct And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
From AC Immune SA
Via GlobeNewswire
News headline image
e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ACIU Stock Earnings: AC Immune Misses EPS for Q1 2024 ↗
ACIU stock results show that AC Immune missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Gold Down Over 1%; AC Immune Shares Spike Higher ↗
 
Via Benzinga
News headline image
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday? ↗
Unlocking hope for Alzheimer's with ACI-24.060. Takeda's agreement with AC Immune targets toxic forms of Abeta, potentially slowing disease progression. 
Via Benzinga
News headline image
Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Crude Oil Surges Over 1%; Amprius Technologies Shares Plunge ↗
 
Via Benzinga
News headline image
Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today? ↗
TransCode Therapeutics stock is down on Monday after the company announced plans for a shareholder meeting for RNAZ investors. 
Via InvestorPlace
News headline image
Why Is Safe & Green Development (SGD) Stock Down 5% Today? ↗
Safe & Green Development stock is down on Monday as SGD investors learn of a Form D filing with the SEC for a securities sale. 
Via InvestorPlace
Topics Regulatory Compliance
News headline image
Why Is AC Immune (ACIU) Stock Up 45% Today? ↗
AC Immune stock is up on Monday after as investors in ACIU react to a new collaboration agreement with Takeda Pharmaceutical. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
News headline image
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
News headline image
ACIU Stock Earnings: AC Immune Beats EPS, Beats Revenue for Q4 2023 ↗
ACIU stock results show that AC Immune beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Raises $50M, Its Alzheimer's Targeting Immunotherapy Advances Into Phase 2b Trial ↗
AC Immune SA's (NASDAQ: ACIU) development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with... 
Via Benzinga
News headline image
AC Immune Announces Pricing of Underwritten Offering of Common Shares
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
From AC Immune SA
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.